News
FibroGen to Report Second-Quarter 2024 Financial Results
FibroGen, Inc.
SAN FRANCISCO, July 30, 2024 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) will announce second-quarter 2024 financial results on Tuesday, August 6, after the market closes. FibroGen will also host a conference call that day at 5:00 p.m. Eastern Time with the investment community to further detail the company’s corporate and financial performance.
Teleconference and Webcast
Toll Free: 1-877-300-8521
International Investors: 1-412-317-6026
Internet broadcast: Click here
To access the call, participants must dial the applicable telephone number above at least 5 minutes prior to the start of the call. A replay of the webcast will also be available for a limited time at “Events and Presentation” in the Investors section of the FibroGen website.
About FibroGen
FibroGen, Inc. is a biopharmaceutical company focused on accelerating the development of novel therapies at the frontiers of cancer biology. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in China, Europe, Japan and several other countries for the treatment of anemia in patients with chronic kidney disease (CKD) on and off dialysis. Roxadustat is in clinical development for chemotherapy-induced anemia (CIA) and a Supplemental New Drug Application (sNDA) has been accepted for review by the China Health Authority. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of a companion PET biomarker targeting CD46. Additionally, FibroGen has expanded its research and development portfolio to include two immuno-oncology product candidates for the treatment of solid tumors. For more information, please visit www.fibrogen.com.
For investor inquiries:
David DeLucia, CFA
Vice President of Corporate FP&A / Investor Relations
InvestorRelations@fibrogen.com
For media inquiries:
Simon Miller
Vice President of Marketing and Corporate Communications
media@fibrogen.com